Hepatic resection and transplantation remain the standard curative therapies for hepatocellular carcinoma ... liver disease are best served by transplant evaluation; however, the best treatment ...

A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the ...

liver transplant is the treatment of choice Nonsurgical treatments (PEI, RFA, and TACE) are employed to minimize drop-out from the transplant waiting list, which nevertheless occurs in 20% of ...

and hepatocellular carcinoma—accounted for 27.3 cases per 1000 deaths. Data gathered between January and September 2023, 1.7 percent of deaths in the Philippines were caused by liver diseases.

Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030Ramat Gan, Israel, Feb. 18, 2025 (GLOBE ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

We have additional data review to complete, which will further define our next steps with TCB008, including as a potential bridge to transplant or other combination efforts." The ACHIEVE trial is an ...

Background: Liver cancer is the third most common cause of cancer related death worldwide, and hepatocellular carcinoma (HCC) accounts for 90% of all primary liver cancers, with pre-existing cirrhosis ...

Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer ... Development of HCC was associated with significantly poorer transplant-free and overall survival (HR 22.61, 95% CI 18.34 to ...

This case report details a patient with hepatocellular carcinoma who developed T1DM and DKA following ... his admission to the Department of Hepatobiliary, Pancreatic, and Transplant Surgery at Xi’an ...

Although, transplant candidates often have to wait for prolonged ... detoxification, and protein synthesis. Hepatocellular carcinoma is the most common form of liver cancer. It can begin as a single ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...